Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.
about
The Role of MicroRNAS in Ankylosing SpondylitisMicroRNA expression and its implications for diagnosis and therapy of tongue squamous cell carcinomaRegulation of Metastasis by microRNAs in Ovarian CancerImpact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological CancerThe role of microRNAs in intrahepatic cholangiocarcinomaRegistered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biologyThe impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.Downregulated lincRNA HOTAIR expression in ovarian cancer stem cells decreases its tumorgeniesis and metastasis by inhibiting epithelial-mesenchymal transitionMiR-506 suppresses tumor proliferation and invasion by targeting FOXQ1 in nasopharyngeal carcinomamiR-203 Acts as a Tumor Suppressor Gene in Osteosarcoma by Regulating RAB22AmiR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCIN1miR-203 Functions as a Tumor Suppressor by Inhibiting Epithelial to Mesenchymal Transition in Ovarian CancerSmall putative NANOG, SOX2, and SSEA-4-positive stem cells resembling very small embryonic-like stem cells in sections of ovarian tissue in patients with ovarian cancerEnrichment for chemoresistant ovarian cancer stem cells from human cell lines.Low-dose cisplatin-induced CXCR4 expression promotes proliferation of ovarian cancer stem-like cells.MicroRNA-765 regulates neural stem cell proliferation and differentiation by modulating Hes1 expression.MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer.Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.Signaling pathways in HPV-associated cancers and therapeutic implications.MicroRNA-142-5p induces cancer stem cell-like properties of Cutaneous Squamous Cell Carcinoma via inhibiting PTEN.The role of miRNAs in the pheochromocytomas.Combination of 5-fluorouracil and 2-morphilino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity.miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma.MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma.miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1.MicroRNA-495 suppresses human renal cell carcinoma malignancy by targeting SATB1.Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.MiR-300 suppresses laryngeal squamous cell carcinoma proliferation and metastasis by targeting ROS1miR-506 inhibits the proliferation and invasion by targeting IGF2BP1 in glioblastoma.The role of the PI3K-Akt signaling pathway in the developmental competence of bovine oocytes.MicroRNA-411 inhibited matrix metalloproteinase 13 expression in human chondrocytes.Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.MicroRNAs: new players in cataract.
P2860
Q26750680-6D92E2A0-FF40-4E62-AB63-F5CC3DB86A38Q26779540-50C75C14-D4EE-44C8-81B6-717D050802AAQ26997006-35C7C7C0-3BE3-48B0-8D81-E38C5096817CQ27016123-8621A434-9FE6-43B2-9D52-1D17FAF3873BQ28067652-BD95DE06-D356-4D62-B14B-2331912E0FC2Q28608111-DB35B1C3-0012-44D1-9E71-B32DC65CEE9AQ34091442-81EC2263-6ACF-458A-B77C-A0D5BF48AF3FQ35194042-E8AE7A50-EB69-4575-99E5-80BDCD261089Q35598357-858CDF2C-622A-4342-AB8C-00C870F84C9DQ35780039-A6DE9FA9-D972-4ABA-82A7-226827770CC3Q36420313-5229465A-864A-4766-868C-2BCC89AE037EQ36497625-4F9843EA-0C58-401F-A941-675F895F6C56Q36651828-F0AB7185-48A2-4131-B909-581BA87517D9Q36788122-E4768494-BFE3-406D-94B5-2032677DD8E6Q36947111-F3F34316-F88F-4BE5-902E-C193B81712F8Q37144094-0F2941A4-743B-410A-AC3D-BCCB2384C7A2Q37604355-8FE5447C-1355-4378-A179-153D2C86276EQ38175044-FC2ADF0B-1817-4ECF-AF74-E3BB92FD39DBQ38206587-3CB105CE-A860-4814-A12D-054ADCAB387FQ38258014-D5DB47AD-93ED-4D3C-9213-58916EFD1988Q38309242-24C428A5-E260-4BA2-9FD9-3875848BA31DQ38370778-0EC95D41-A06D-447A-9504-244CD3ED98DAQ38600615-257C9EE4-694E-47BE-B832-9D054BBA7DC4Q38606234-7B8CB505-673A-4889-8BC4-C17ACE51179EQ38793468-D65E9305-2893-49BB-B1A9-CC92492E9154Q38804354-E588CA49-0B2D-43A0-8E62-A4135FC24472Q38812266-BA54B241-9936-4F0E-A597-2B1014CAC934Q38814833-48DF7E82-2F27-4F45-A1F9-7620C826600EQ38819843-264D6CBA-1F13-4A45-93B7-288F0A679881Q38838597-FD4C4AA9-930C-42DE-BE6D-19BBACD5321CQ38841955-AF49307F-E2FE-4C26-9EDA-2E2CD1A2B5B9Q38843399-5A30BDD4-629B-4D4C-8D55-1B9238D514F7Q38929235-6CD85FA2-706C-4C58-B5C5-3E82C9A76A10Q39174042-4985A7F9-6AA1-4278-A92D-2C416B843A43Q39303945-6F4AA65B-21C7-4630-9C5D-90E3959AFAF3Q40182494-9A1040D1-8B1B-414B-9AD0-E2F2E76E6FAAQ41702436-D1943DBD-B036-46BF-83BB-B0993ED871FFQ42068871-0DB70C66-DD15-498A-B3A1-4D8D826F0CB6Q42215256-5DB1A661-9F09-42A8-9E41-7323DE53468DQ42367908-904AC486-C1B3-4B93-B671-2BB8005D08F9
P2860
Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Enrichment of ovarian cancer s ...... n miRNA-activated AKT pathway.
@en
Enrichment of ovarian cancer s ...... n miRNA-activated AKT pathway.
@nl
type
label
Enrichment of ovarian cancer s ...... n miRNA-activated AKT pathway.
@en
Enrichment of ovarian cancer s ...... n miRNA-activated AKT pathway.
@nl
prefLabel
Enrichment of ovarian cancer s ...... n miRNA-activated AKT pathway.
@en
Enrichment of ovarian cancer s ...... n miRNA-activated AKT pathway.
@nl
P2093
P2860
P356
P1433
P1476
Enrichment of ovarian cancer s ...... n miRNA-activated AKT pathway.
@en
P2093
P2860
P304
P356
10.1111/CPR.12038
P577
2013-08-01T00:00:00Z